KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients.

Br J Cancer · 2013 · PMC3553525 · PMID 23175150

Europe PMC DOI

hedged sentence

0.1600

closest p · 3.2× alpha

0.1600

boldest claim

The sentences

did not reach statistical significanceP =0.16not close (p > 0.1)

This advantage did not reach statistical significance (HR 1.404; P =0.16), but it is nonetheless interesting, given the exploratory nature of the analysis and the large number of patients censored.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.